Jonathan W. Friedberg on Muck Rack

Jonathan W. Friedberg

Rochester
As seen in: Journal of Global Oncology, Nature, Wiley Online Library, The New England Journal of Medicine, EClinicalMedicine, The Lancet, Democrat and Chronicle, Journal of Clinical Oncology, HMP Global Learning Network, Future Medicine, CURE Magazine and
Lymphoma expert. Director of @WilmotCancer Rochester NY. Editor-in-Chief, Journal of Clinical Oncology @asco_pubs. Tweets and opinions are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonathan W.

Contact Jonathan W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine in Advanced Hodgkin Lymphoma

|
By Jonathan W. Friedberg
| Oncology Learning Network
Clinical Summary: Design/Population: The phase 3 SWOG S1826 trial was a multinational, cooperative group study which randomized adolescent and adult patients with advanced Hodgkin lymphoma to receive either nivolumab or brentuximab vedotin plus plus doxorubicin, vinblastine, and dacarbazine. Key Outcomes: Nivolumab demonstrated superior progression-free survival, leading to early trial closure due to efficacy.
Open in Who Shared Issue with article?

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma - Leukemia

|
By Daniel Filip, Katerina Litzmanova, Androniki Michaelou, Filip Kledus, Jan Devan, Miroslav Boudny, Eva Hoferkova, Sonali Sharma, Vaclav Seda, Pedro Faria Zeni, Marek Borsky, Kvetoslava Matulova, Leos Kren, Jan Oppelt, Nicolas Blavet, Václav Hejret, Milan Urik, Andrea Mareckova, Lisa M. Rimsza, Katerina Kamaradova, David Belada, Alice Sykorova, Heidi Mocikova, Marek Trneny, Zuzana Prouzova, Andrew Evans, Alexey V. Danilov, Heike Horn, German Ott, Philipp B. Staber, Jiří Mayer, Jonathan W. Friedberg, Andrea Janíková, Marek Mraz
| Nature
Abstract Follicular lymphoma (FL) patients are at risk of disease transformation to aggressive high-grade lymphoma (tFL). While several genetic alterations have been implicated in tFL, the role of microenvironmental interactions and post-transcriptional regulation by non-coding RNAs remains poorly understood. We performed the first matched profiling of mRNAs and short non-coding RNAs (miRNAs) in paired FL and tFL samples (n = 11 pairs).
Open in Who Shared Issue with article?

Sun Sets on Rituximab/Gemcitabine/Oxaliplatin as Bispecific Antibodies Rise: The SUNMO Trial

|
By Danielle Wallace , Jonathan W. Friedberg
| brnw.ch
Diffuse large B-cell lymphoma (DLBCL) is highly curable with standard chemoimmunotherapy; however, approximately one third of patients experience disease progression during or after treatment.1 For many patients with relapsed or refractory (R/R) DLBCL, chimeric antigen receptor T-cell (CAR-T) therapy demonstrates curative potential and superior outcomes compared with the historical standard of high-dose therapy and autologous stem cell transplantion (ASCT).2,3 However, relapses after CAR-T...
Open in Who Shared Issue with article?
See all 42 licensed articles (54 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Jonathan W.

Contact Jonathan W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified